NCT01290393 2018-07-26
Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada
GlaxoSmithKline
Terminated
Clinical Trials
9 trialsNCT01101542 2018-07-23
Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females
GlaxoSmithKline
Completed
NCT01953822 2016-12-26
Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom
GlaxoSmithKline
Completed
NCT01498627 2015-04-06
PGRx
GlaxoSmithKline
Completed
NCT01153906 2014-12-02
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination
GlaxoSmithKline
Completed
NCT01905462 2013-09-30
Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK
GlaxoSmithKline
Completed
NCT01551537 2013-09-09
Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka
GlaxoSmithKline
Withdrawn
NCT01207999 2012-11-22
Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer
GlaxoSmithKline
Completed
NCT01213459 2012-11-22
Study on the Prevalence of Human Papillomavirus Types in Women >= 15 Years of Age in the Kingdom of Saudi Arabia
GlaxoSmithKline
Completed